Abstract:Tau-targeting therapies for Alzheimer’s disease (AD) have received increasing attention in recent years, due to the clinical failure of various anti-amyloid β drugs and closer association between tau burden and cognitive impairments in AD patients. The intracellular tau aggregation is recognized as a vital event in tau pathway of AD progression. However, current developed tau aggregation inhibitors are still facing serious challenges on how to access the cytosol of cells where tau protein mainly located and differentiate pathological tau from normal tau. Herein, we report a customized biomimetic nanochaperone for targeting intracellular pathological tau, serving as a novel anti-tau therapy of AD. This nanochaperone was tailored by engineering VQIINK hexapeptide derived from tau protein onto the surface of self-assembly micelle equipped with chaperone-like hydrophobic microdomains and confined spaces. With the lysosomal microenvironment responsiveness of unique surface structure, the Tau-nChap can escape from lysosome and enter into cytoplasm to overcome the intracellular tau location challenge. More importantly, the cytosol-arrived nanochaperone can selectively capture pathological tau without interfering with normal tau and potently inhibit their aggregation through the synergic effect of tau-recognizing peptide and confined hydrophobic microdomain on surface. As a result, the tau-targeting nanochaperone rescues neuronal cells from tau-mediated neurotoxicity and ameliorates cognitive deficits of AD model mice. Therefore, we believe that this custom-built tau-nanochaperone represents a promising weapon for combating AD and provides valuable insights for the treatment of other neurodegenerative disorders induced by specific pathogenic proteins including Parkinson’s disease and Huntington’s disease.

Hsp90 Co-Chaperone Degradation Combined with Antioxidation Nanostrategy to Rescue Tauopathy-Induced Alzheimer’s Disease

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Self-assembly Hollow Manganese Prussian White Nanocapsules Attenuate Tau-related Neuropathology and Cognitive Decline.

Inhibition of Aβ Aggregation and Tau Phosphorylation with Functionalized Biomimetic Nanoparticles for Synergic Alzheimer’s Disease Therapy

Engineering a pathological tau-targeted nanochaperone for selective and synergetic inhibition of tau pathology in Alzheimer's Disease

Harnessing Nanochaperone-Mediated Autophagy for Selective Clearance of Pathogenic Tau Protein in Alzheimer's Disease

Systemic Administration of Neurotransmitter-Derived Lipidoids-PROTACs-DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy

“Cascaded Rocket” Nanosystems with Spatiotemporal Separation for Triple‐Synergistic Therapy of Alzheimer's Disease

Intelligently Thermoresponsive Flower-Like Hollow Nano-Ruthenium System for Sustained Release of Nerve Growth Factor to Inhibit Hyperphosphorylation of Tau and Neuronal Damage for the Treatment of Alzheimer's Disease

Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer's Disease.

Inhibition of Aβ Aggregation and Tau Phosphorylation with Functionalized Biomimetic Nanoparticles for Synergic Alzheimer's Disease Therapy

Ultrasound-Excited Protoporphyrin IX-Modified Multifunctional Nanoparticles As a Strong Inhibitor of Tau Phosphorylation and Β-Amyloid Aggregation.

A New Chiral Pyrrolyl α-Nitronyl Nitroxide Radical Attenuates β-Amyloid Deposition and Rescues Memory Deficits in a Mouse Model of Alzheimer Disease

A New Chiral Pyrrolyl Alpha-Nitronyl Nitroxide Radical Attenuates Beta-Amyloid Deposition And Rescues Memory Deficits In A Mouse Model Of Alzheimer Disease

Pathological BBB Crossing Melanin-Like Nanoparticles as Metal-Ion Chelators and Neuroinflammation Regulators against Alzheimer’s Disease

A biomimetic upconversion nanoreactors for near-infrared driven H2 release to inhibit tauopathy in Alzheimer's disease therapy

Pathological BBB Crossing Melanin-Like Nanoparticles As Metal-Ion Chelators and Neuroinflammation Regulators Against Alzheimer's Disease.

Blood-brain barrier Permeable nanoparticles for Alzheimer's disease treatment by selective mitophagy of microglia

Zn2+-responsive Palladium Nanoclusters Synergistically Manage Alzheimer’s Disease Through Neuroprotection and Inhibition of Oxidative Stress

Synthetic chaperone based on Hsp90-Tau interaction inhibits pathological Tau aggregation and rescues physiological Tau-Microtubule interaction

Tau‑targeting multifunctional nanocomposite based on tannic acid-metal for near-infrared fluorescence/magnetic resonance bimodal imaging-guided combinational therapy in Alzheimer's disease